5-HT1A receptor antagonists neither potentiate nor inhibit the effects of fluoxetine and befloxatone in the forced swim test in rats.

Recent clinical data suggest that coadministration of pindolol with an antidepressant, particularly the 5-hydroxytryptamine (5-HT) reuptake inhibitor fluoxetine, can shorten the time to onset of clinical activity and increase the proportion of responders. We have examined the interaction of antidepressants with 5-HT1A receptors using the forced swim test in rats using both (+/-)-pindolol and the selective 5-HT1A receptor antagonist WAY 100,635 (N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-(pyridinyl) cyclohexanecarboxamide trihydrochloride) in combination with either fluoxetine or the selective monoamine oxidase-A inhibitor befloxatone. 8-Hydroxy-dipropylaminotetralin (8-OH-DPAT; 0.125-1 mg/kg s.c.), used as a reference for 5-HT1A agonist activity, reduced immobility in the forced swim test and this effect was significantly antagonised by WAY 100,635. WAY 100,635 alone (0.01-0.1 mg/kg s.c.) was without effect, although a higher dose, 0.3 mg/kg s.c., had a nonsignificant tendency to increase immobility. In contrast, (+/-)-pindolol (1-16 mg/kg s.c.) significantly reduced immobility, but to a lesser extent than 8-OH-DPAT. As expected, the antidepressants fluoxetine (10-80 mg/kg p.o.) and befloxatone (0.03-1 mg/kg p.o.) dose-dependently reduced immobility time. When the antidepressants were combined with WAY 100,635 (0.1 mg/kg), WAY 100,635 either had no effect or, at relatively high doses, significantly reduced their activity in this test. Combination of the antidepressants with (+/-)-pindolol (2 or 4 mg/kg s.c.) failed to reveal a significant interaction. These results demonstrate that the anti-immobility effects of fluoxetine and befloxatone are neither facilitated nor antagonised by doses of WAY 100,635 that completely reverse the effects of 8-OH-DPAT. Furthermore, there was no evidence that coadministration of the antidepressants with (+/-)-pindolol was able to facilitate their antidepressant-like effects. Thus, whereas direct agonist activity at 5-HT1A receptors can modulate immobility in the forced swim test, this receptor subtype does not appear to play a major role in the antidepressant-like effects of fluoxetine or befloxatone under the conditions used in this study.

[1]  Alain M. Gardier,et al.  Regional differences in the effect of the combined treatment of WAY 100635 and fluoxetine: an in vivo microdialysis study , 1996, Naunyn-Schmiedeberg's Archives of Pharmacology.

[2]  C. Robert Cloninger,et al.  Serotonergic autoreceptor blockade in the reduction of antidepressant latency: personality variables and response to paroxetine and pindolol. , 1997, Journal of affective disorders.

[3]  Andrés G. Fernández,et al.  GR 127935 blocks the locomotor and antidepressant-like effects of RU 24969 and the action of antidepressants in the mouse tail suspension test , 1996, Pharmacology Biochemistry and Behavior.

[4]  M. Tome,et al.  Paroxetine and pindolol: a randomized trial of serotonergic autoreceptor blockade in the reduction of antidepressant latency , 1997, International clinical psychopharmacology.

[5]  P. Cowen,et al.  Electrophysiological and neurochemical evidence that pindolol has agonist properties at the 5‐HT1A autoreceptor in vivo , 1998, British journal of pharmacology.

[6]  R. Samanin,et al.  Role of 5-HT1A receptors in the effects of acute and chronic fluoxetine on extracellular serotonin in the frontal cortex , 1996, Pharmacology Biochemistry and Behavior.

[7]  V. Pérez,et al.  Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors. , 1994, Archives of general psychiatry.

[8]  I. Lucki,et al.  Regional differences in the effects of forced swimming on extracellular levels of 5-hydroxytryptamine and 5-hydroxyindoleacetic acid , 1995, Brain Research.

[9]  H. Stassen,et al.  Delayed onset of action of antidepressant drugs? Survey of results of Zurich meta-analyses. , 1996, Pharmacopsychiatry.

[10]  G. Johnson,et al.  A Review of the Use of Augmentation Therapy for the Treatment of Resistant Depression: Implications for the Clinician , 1997, The Australian and New Zealand journal of psychiatry.

[11]  J. Gosden,et al.  Mediation of the antidepressant‐like effect of 8‐OH‐DPAT in mice by postsynaptic 5‐HT1A receptors , 1993, British journal of pharmacology.

[12]  V. Pérez,et al.  Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment , 1997, The Lancet.

[13]  G. Parker.  On Brightening Up: Triggers and Trajectories to Recovery from Depression , 1996, British Journal of Psychiatry.

[14]  C. de Montigny,et al.  Effect of the reversible monoamine oxidase-A inhibitor befloxatone on the rat 5-hydroxytryptamine neurotransmission. , 1998, European journal of pharmacology.

[15]  O. Bergis,et al.  Befloxatone, a new reversible and selective monoamine oxidase-A inhibitor. II. Pharmacological profile. , 1996, The Journal of pharmacology and experimental therapeutics.

[16]  C. Montigny,et al.  Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists , 1996, Trends in Neurosciences.

[17]  Trevor R. Norman,et al.  Combining pindolol and paroxetine in an animal model of chronic antidepressant action--can early onset of action be detected? , 1998, European journal of pharmacology.

[18]  C. Montigny,et al.  Selective Activation of Postsynaptic 5-HT1A Receptors Induces Rapid Antidepressant Response , 1997, Neuropsychopharmacology.

[19]  P. Blier,et al.  Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression. , 1995, Journal of clinical psychopharmacology.

[20]  C. Gundlah,et al.  Increase in extracellular serotonin produced by uptake inhibitors is enhanced after chronic treatment with fluoxetine , 1994, Neuroscience Letters.

[21]  S. Hjorth,et al.  (-)-Pindolol, but not buspirone, potentiates the citalopram-induced rise in extracellular 5-hydroxytryptamine. , 1996, European journal of pharmacology.

[22]  Y. Ichimaru,et al.  Neither the 5-HT1A- nor the 5-HT2-receptor subtype mediates the effect of fluvoxamine, a selective serotonin reuptake inhibitor, on forced-swimming-induced immobility in mice. , 1995, Japanese journal of pharmacology.

[23]  M. Bourin,et al.  The role of 5-HT1A and 5-HT1B receptors in antidepressant drug actions in the mouse forced swimming test. , 1996, European journal of pharmacology.

[24]  M. Langlois,et al.  Synergistic neurochemical and behavioral effects of fluoxetine and 5-HT1A receptor antagonists. , 1998, European journal of pharmacology.

[25]  J. Kleinman,et al.  The neuropathology of schizophrenia. , 1988, Schizophrenia bulletin.

[26]  P. Cowen,et al.  Effects of MDL 73005EF on central pre- and postsynaptic 5-HT1A receptor function in the rat in vivo. , 1990, European journal of pharmacology.

[27]  O. Curet,et al.  Befloxatone, a new reversible and selective monoamine oxidase-A inhibitor. I. Biochemical profile. , 1996, The Journal of pharmacology and experimental therapeutics.

[28]  P. Grillner,et al.  5-HT1A receptor antagonists increase the activity of serotonergic cells in the dorsal raphe nucleus in rats treated acutely or chronically with citalopram , 1995, Naunyn-Schmiedeberg's Archives of Pharmacology.

[29]  S. Hjorth,et al.  5-HT1A autoreceptors and the mode of action of selective serotonin reuptake inhibitors (SSRI) , 1995, Behavioural Brain Research.

[30]  S. Hjorth,et al.  Further evidence for the importance of 5-HT1A autoreceptors in the action of selective serotonin reuptake inhibitors. , 1994, European journal of pharmacology.

[31]  S. Mir,et al.  Pindolol augmentation of antidepressant therapy , 1998, British Journal of Psychiatry.

[32]  C. Nemeroff.  Augmentation strategies in patients with refractory depression , 1996, Depression and anxiety.

[33]  THE EFFECTS OF PINDOLOL ADDITION TO FLUVOXAMINE AND BUSPIRONE IN CHRONIC MILD STRESS MODEL OF DEPRESSION , 1996 .

[34]  E. Przegaliński,et al.  The role of hippocampal 5-hydroxytryptamine1a (5-HT1a) receptors in the anticonflict activity of β-adrenoceptor antagonists , 1995, Neuropharmacology.

[35]  I A Cliffe,et al.  A pharmacological profile of the selective silent 5-HT1A receptor antagonist, WAY-100635. , 1995, European journal of pharmacology.

[36]  F. Borsini,et al.  Role of the serotonergic system in the forced swimming test , 1995, Neuroscience & Biobehavioral Reviews.

[37]  R. Porsolt,et al.  Behavioural despair in rats: a new model sensitive to antidepressant treatments. , 1978, European journal of pharmacology.

[38]  C. Dourish,et al.  Inhibition of 8-OH-DPAT-induced elevation of plasma corticotrophin by the 5-HT1A receptor antagonist WAY100635. , 1994, European journal of pharmacology.

[39]  F. Artigas,et al.  Role of 5‐HT1A autoreceptors in the mechanism of action of serotoninergic antidepressant drugs: recent findings from in vivo microdialysis studies , 1996, Fundamental & clinical pharmacology.

[40]  M. Maes,et al.  Efficacy of treatment with trazodone in combination with pindolol or fluoxetine in major depression. , 1996, Journal of affective disorders.

[41]  D. Bakish,et al.  Fast onset: an open study of the treatment of major depressive disorder with nefazodone and pindolol combination therapy , 1997 .

[42]  M. Szuba,et al.  The antidepressant response to tricyclics in major depressives is accelerated with adjunctive use of methylphenidate. , 1994, Psychopharmacology bulletin.